Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stroke/systemic embolism (SSE) is unknown.
O
ral anticoagulants (OACs) substantially reduce stroke risk for patients with atrial fibrillation (AF). [1] [2] [3] [4] Despite the positive net clinical benefit of OACs in the majority of patients with AF, 5 between 30% and 50% of patients meeting indications for OACs with AF are not on treatment. 6, 7 Bleeding risk is commonly cited as a reason for stopping OAC therapy in high-risk patients. 8, 9 Nuisance bleeding events (ie, bruising, epistaxis, hemorrhoidal bleeding; NB) are substantially more common than more serious adverse bleeding events and, as an indicator of bleeding tendency, 10 may influence decisions regarding discontinuation of OAC therapy, especially in older patients. 11 Prior reports in patients undergoing drug-eluting stent implantation have found rates of antithrombotic discontinuation attributable to NB as high as 11.1%, 12 despite guideline recommendations to continue therapy among patients experiencing minor bleeding events. 13 However, OAC use following minor bleeding events in AF has not been well described, and few data are available as to whether milder bleeding events are a prognostic factor for major bleeding events in patients with AF on OACs. In addition, a prior study has reported impairments in quality of life with NB among patients receiving antiplatelet therapy after myocardial infarction, 14 but this association has not been examined in patients with AF on OAC.
Accordingly, we examined the association between nonmajor bleeding events and future adverse clinical events in a US-based AF population. Our main objective was to evaluate the prognostic significance of NB for future adverse clinical events including stroke/ non-central nervous system systemic embolism (SSE) and major bleeding; we hypothesized that NB was associated with risk of future adverse clinical events. In a subset of patients who completed a self-reported anticoagulation satisfaction scale, we reported changes in perceived burden and benefit of OACs after experiencing NB.
METHODS

Study Population
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. We analyzed data from the ORBIT-AF study (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Details of the ORBIT-AF design have been published. 15 In brief, ORBIT-AF was a national, prospective, outpatient registry of AF in patients ≥18 years at 176 sites in the United States selected to ensure representation from multiple specialties, including primary care, electrophysiology, and cardiology. Information on demographics, AF history, medical comorbidities, procedures, medication use, disease progression, and clinical events was captured through medical record review at study visits at ≈6-month intervals.
From 2010 to 2011, a total of 10 135 patients were enrolled in ORBIT-AF, representing 50 554 visits during the follow-up period. We used the patient visit as the unit of analysis and excluded visits that were ineligible (ie, initial and last follow-up visits) (n=19 888), visits where the patient was not on OACs (n=7334; this exclusion was not made for analyses of OAC discontinuation), and visits occurring after the patient experienced a first stroke or major bleeding event (n=4772). The final study population was N=6771 patients (n=18 560 visits) for analyses of the major bleeding and SSE end points (85.2% visits on warfarin and 14.8% visits on non-vitamin K antagonist).
ORBIT Bleeding Event Definitions
NB was abstracted from the medical record and collected as a binary variable at each ORBIT-AF follow-up visit. In ORBIT-AF, NB was 1 of 3 bleeding event types collected during follow-up (in order of increasing severity): (1) NB, defined as occurrence of "any bruising, hemorrhoidal bleeding, or other mild bleeding not requiring medical attention" (yes or no); (2) clinically relevant, nonmajor bleeding (CRNM) defined as any documented bleeding event requiring a visit with a healthcare professional but not meeting formal major bleeding criteria defined by the International Society on Thrombosis and Haemostasis (ISTH) 16 ; and (3) major bleeding , defined as a bleeding event meeting ISTH major bleeding criteria. 16 Because the NB definition was designed to represent any minor bleeding event not requiring medical attention, information on the specific type and site of nuisance bleed was not available. The primary NB definition included any NB during the prior 6 months. In a secondary analysis, we also created a composite event of either NB or CRNM bleeding.
Clinical Outcomes
The primary outcomes of interest were ISTH major bleeding and SSE. We also examined the occurrence of discontinuation
Clinical Perspective
What Is New?
• In a US-based outpatient atrial fibrillation registry, nuisance bleeding is common among patients taking oral anticoagulants.
• OAC was discontinued in fewer than 4% of patients experiencing nuisance bleeding.
• The occurrence of nuisance bleeding was not associated with either an increased risk of major bleeding or stroke/systemic embolism in the subsequent 6 months.
What Are the Clinical Implications?
• These findings provide reassurance that continuation of oral anticoagulants in patients experiencing nuisance bleeding does not appear to lead to increased risk for major adverse events. 
Anti-Clot Treatment Scale Score
In a secondary analysis, we evaluated subscale and total scores from the Anti-Clot Treatment Scale (ACTS), a 15-item patient-reported instrument measuring satisfaction with anticoagulation treatment. 17 The ACTS survey measures the perceived impact of anticoagulation side effects (eg, bruising, bleeding, food/beverage restrictions) on activities of daily living (eg, exercise, housework) in addition to the patients' general satisfaction with their anticoagulant treatment. The ACTS survey was administered to a subsample of the ORBIT-AF population at baseline (n=1838), 6-month (n=1496), 12-month (n=1233), and 24-month (n=903) visits. Of the 6771 patients in the study population, 320 patients experiencing NB and 1015 not experiencing NB completed the ACTS survey at baseline. Of those experiencing NB, 288 patients completed the ACTS survey before and after the NB. Baseline characteristics by completion of the ACTS survey are provided in Table I in the online-only Data Supplement. We examined baseline values and change over time of the ACTS total score, the 12-item burden subscale, and the 3-item benefits subscale among patients experiencing a NB during follow-up to investigate changes in quality of life following a NB event. A change in score was defined as the difference between the most proximal ACTS score after the NB and the most proximal ACTS score before the NB.
Statistical Analysis
The distributions of baseline characteristics of patients experiencing a first NB during follow-up versus those who did not are presented as medians for continuous variables (25th to 75th percentiles) and differences between the groups are assessed by the Wilcoxon rank sum test. Frequencies (percentages) are presented for categorical variables, and differences between the groups are assessed by the χ 2 test. Frequencies of OAC therapy after experiencing a NB in the prior 6 months by OAC therapy before the NB are presented as percentages with 95% confidence intervals. Outcomes during the 180 days postvisit were modeled by pooled logistic regression with patient visit as the unit of analysis. 18 The primary NB definition included any NB occurring during the 6 months preceding a given study visit (yes or no). This definition aligns with NB that would be reported during regular clinic visits. Then, we compared clinical outcomes in the 180 days after the visit by whether NB had occurred in the 6 months leading up to the visit (see Figure I in the online-only Data Supplement for additional details). We repeated this for each study visit during follow-up (6 months, 12 months, 18 months, etc) and pooled results across visits; NB, therefore, was treated as time varying for the purposes of this analysis. To compare recent NB with no NB, only the first visit after NB was included and subsequent visits (with an old history of NB) were excluded. In sensitivity analysis, we changed this framework and compared any prior NB with no prior NB, including all visits after a NB. Because of the 6-month follow-up data collection in ORBIT, censoring (loss to follow-up) occurs at the last visit attended; therefore, follow-up within 180-day intervals is complete. If the competing risk of death occurred during the 180 days of follow-up without occurrence of a stroke or bleeding event, the patient was treated as event-free. This corresponds to estimation of the 180-day cumulative incidence of type-specific events. A robust, empirical variance was used to account for the potential correlation attributable to the repeated visits by the same individual. Missing data at baseline were handled with single imputation, and imputed values were obtained by Markov chain, Monte Carlo, or regression methods. The last value carried forward method was used for missing values in follow-up. ACTS data were analyzed descriptively with medians and interquartile ranges at baseline between patients experiencing NB and those who did not. We also evaluated change in ACTS data among patients experiencing NB, in addition to describing the frequency of dose changes following the NB event.
Adjustment Variables
The ATRIA bleeding risk score and the CHA 2 DS 2 -VASc stroke risk score were included as a series of dummy variables representing the score value minus the reference category for adjustment for the major bleeding and stroke outcomes models, respectively. The components comprising each score were time-updated along with the score. The CHA 2 DS 2 -VASc score includes 7 components: age, history of stroke/transient ischemic attack, heart failure/left ventricular dysfunction, hypertension, diabetes mellitus, female sex, and vascular disease (range, 0-9). 19 The ATRIA bleeding score includes 5 components: age, renal disease, anemia, prior bleeding, and hypertension (range, 0-10). 20 
Sensitivity Analysis
We repeated the above analyses to examine the prognostic significance of a composite of NB and CRNM events for stroke and bleeding outcomes. For this sensitivity analysis, we applied the same exclusion criteria, with the additional exclusion of no prior CRNM bleed. The final population for this analysis was 6967 patients (n=19 031 visits).
For all analyses, P values are 2-sided and P<0.05 was considered to be statistically significant. All statistical analyses were performed using SAS software (version 9.4). ORBIT-AF participants gave written informed consent before study enrollment. The Duke Institutional Review Board provided ethical oversight for the ORBIT-AF Registry, and participating sites received approval from local of central institutional review boards, as appropriate, before enrolling patients.
RESULTS
Over a median 1.5 years of follow-up, n=1357 patients experienced a NB (20.0%; 14.8 per 100 subject-years). Patients experiencing a NB were more likely to be white than those not experiencing a NB ( Patterns of antithrombotic therapy before and after the NB event are shown in Table 2 . The majority of anticoagulated patients who experienced a NB (63.2%) were taking OACs without other antithrombotic therapy before the bleed, with over one-third taking OACs and either single or dual antiplatelet therapy. Following the NB event, 96.4% of those who were anticoagulated remained on OACs, with 2.3% of patients taking an antiplatelet only and 1.3% of patients taking no antithrombotic therapy. We also examined the frequency of dose reduction among anticoagulated patients who experienced NB and those who did not. Among 1239 anticoagulated patients who experienced NB (on the same type of OAC before and after the bleed), 27.2% were switched to a lower OAC dose at the next visit following the NB event (29.1% of warfarin patients and 6.1% of patients taking non-vitamin K antagonist oral anticoagulants). Among 3494 patients who did not experience NB and were on the same type of OAC medication, 24.4% switched to a lower OAC dose from 6 to 12 months.
Major bleeding occurred in 287 of 6771 patients (n=18 560 visits). In unadjusted regression models, NB was not associated (odds ratio [OR]; 95% confi- Table 3) . After adjustment for ATRIA bleeding score, there remained no association between NB and risk of subsequent major bleeding over 6 months (OR, 1.04; 95% CI, 0.68-1.60; P=0.86). Increasing ATRIA score was associated with increasing risk of major bleeding (Figure) , but estimated event rates for each score value were similar for patients who experienced a NB and those who did not.
Stroke/SSE occurred in 64 of 6771 patients (n=18 560 visits). In unadjusted models, NB was also not associated with subsequent risk for an SSE event (OR, 1.31; 95% CI, 0.57-3.05; P=0.53). Similar patterns were observed following adjustment for CHA 2 DS 2 -VASc risk score (OR, 1.24; 95% CI, 0.53-2.91; P=0.62). As shown in Figure, increasing CHA 2 DS 2 -VASc score was associated with increasing risk of SSE, but patients experiencing a NB had similar events rates as those who did not for each score value. 
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We examined the association between a composite of nuisance/CRNM bleeding and stroke and major bleeding outcomes in sensitivity analyses. A total of n=1828 (26.3%; 19.5 per 100 subject-years) composite events occurred over a median of 1.5 years of follow-up. In regression models adjusting for ATRIA score, the composite of NB and CRNM bleeding was not associated with ISTH major bleeding (OR, 1.29; 95% CI, 0.91-1.81; P=0.15) at 6 months. Similar nonsignificant associations were found for the association of the composite and SSE in models adjusting for CHA 2 DS 2 -VASc risk (OR, 1.52; 95% CI, 0.77-3.01; P=0.23). In additional sensitivity analyses, we expanded the definition of NB from events in the prior 6 months to any prior NB reported over follow-up. Results were consistent with those from analyses of NB and the composite of NB and CRNM in the prior 6 months and clinical outcomes (Tables II and III in the online-only Data Supplement). However, we did note a small positive association between the composite of any NB and CRNM bleeding and future major bleeding when the definition of past bleeding was expanded to include any past bleeding events (OR, 1.29; 95% CI,1.02-1.62; P=0.03).
In a secondary analysis, we examined patterns of anticoagulation treatment satisfaction in patients who completed the ACTS scale. Baseline ACTS scores were similar among patients who went on to experience a NB and those who did not (Table 4) . Among 288 patients experiencing a NB with complete ACTS data, there was no change in self-reported anticoagulation satisfaction from before to after the NB.
DISCUSSION
Recent studies suggest that OACs are discontinued at much higher rates in community practice than in clinical trials, [21] [22] [23] resulting in increased risk of thromboembolic stroke. Major contributors to premature discontinuation may include perceived bleeding risk after NB and patient preference, 8 yet few studies have examined the incremental prognostic information of NB for patients taking OACs. We found that <4% of patients had OACs discontinued after a NB in routine practice, and the occurrence of NB was not associated with either an increased risk of major bleeding or SSE in the subsequent 6 months. Moreover, the occurrence of NB was not associated with changes in anticoagulation treatment satisfaction among patients over time. Collectively, our findings provide reassurance that continuation of OACs in patients with NB appears to not lead to increased risk for major adverse events. Despite established evidence for safety and efficacy in real-world populations, OACs continue to be underused in AF, 24 in part, because of perceived bleeding risk. Coupled with the increasing risk of intracranial hemorrhage with advanced age, 25 concerns about bleeding risk represent a key barrier to optimal anticoagulation, in particular, among older patients who are more likely to be frail and are at increased risk for falls. 26 In a recent review of electronic health record data, fall risk and recent bleeding represented over half of documented reasons for not prescribing warfarin. 11 Such treatment patterns are in conflict with evidence demonstrating the persistent net clinical benefit of OACs, even for patients at high risk for falls. 27 In work using Markov decision modeling, propensity to fall did not influence the estimated benefit of warfarin therapy, regardless of age and the presence of other risk factors. 28 In our study, patients with AF experiencing NB were slightly more likely to have experienced a prior bleed than those who did not. Despite the presence of additional risk factors, we did not find a significant association between NB and future major bleeding events after adjusting for known bleeding risk.
OACs are effective for patients with AF at most levels of stroke and bleeding risk. Existing scores for estimating bleeding risk in AF have shown variable performance, and there is interest in identifying additional prognostic factors to improve precision in risk stratification. NB may be seen as a marker of bleeding tendency. 10 The lack of an association between NB and more In addition, the proportion of patients discontinuing anticoagulation following a NB event in our study was relatively low (<5%), suggesting that occurrence of NB in routine practice did not influence the decision to anticoagulate for most patients who were already treated. When examining antithrombotic therapies among patients with nuisance bleeding, we observed low occurrence of switching from OAC to aspirin monotherapy, consistent with prior evidence suggesting that aspirin is neither safe nor effective for stroke prevention in older patients with AF. [29] [30] [31] Patient preferences are a key component of optimal anticoagulation decision making. Prior work on patient preferences in AF suggests a higher priority placed on avoidance of stroke than avoidance of bleeding, with patients willing to endure 4.4 major bleeds on average to prevent a single stroke. 32 However, prior work in patients with myocardial infarction has also shown adverse impacts of NB on patient-reported outcomes including quality of life.
14 Given that milder bleeding may disrupt activities of daily living, we hypothesized that patients experiencing NB may also experience impairments in their quality of life. We tested this hypothesis in a subset of patients with complete data on anticoagulation satisfaction and did not observe clinically meaningful differences in ACTS score at baseline by NB over follow-up. Furthermore, there were no within-patient changes in self-reported OAC treatment satisfaction among those experiencing a nuisance bleed during follow-up. Future work is needed to fully characterize the association between patient preferences, treatment patterns, and quality of life in AF.
Limitations
The ORBIT-AF registry is voluntary in nature; as such, it may not be representative of all AF patients or providers who treat patients with AF, so the results may not generalize to all AF practices. We observed very low OAC discontinuation following NB; associations with clinical outcomes may differ in other populations with higher rates of OAC discontinuation or switching to aspirin. Furthermore, although we present descriptive data on OAC dose changes following NB, these changes may have been informed by clinical data other than NB that are not collected in ORBIT (ie, modifications to target international normalized ratio in warfarin-treated patients) and should therefore be treated as preliminary. Although ORBIT-AF collected information on type of OACs, we were underpowered to examine whether associations were consistent across specific types of OAC therapy. In multivariable models, we adjusted for commonly used stroke and bleeding risk scores to evaluate the incremental prognostic value of mild bleeding events; however, residual confounding of effect estimates is possible because of the observational nature of these analyses. Nuisance bleeding was collected as a binary variable representing any minor bleeding event not requiring medical attention; therefore, information on the specific type and site of nuisance bleed was not available. Because NB was captured every 6 months, it is possible that some events were forgotten and not reported. However, this would likely bias NB capture to more severe episodes, yet no association was observed. The number of major bleeding events over the duration of the follow-up in study was relatively low and the 95% confidence interval for the association with NB contains some values that would be of modest clinical significance. However, we observed strong, significant associations with CHA 2 DS 2 -VASc and ATRIA risk scores, and it seems unlikely that the lack of observed associations with NB were because of limited power. Because ACTS data were only collected on a subsample of participants, selection bias may have occurred and quality-of-life data may not be reflective of the entire ORBIT-AF cohort. Finally, because occurrence of NB and antithrombotic management patterns were collected simultaneously at follow-up visits, we were unable to definitively establish temporality of medication decisions and bleeding events. Therefore, all estimates should be interpreted as associations rather than as causal effects. However, our analysis is closely aligned with the question of prognosis at regular clinic visits.
Conclusion
Nuisance bleeding is common among patients with AF taking OACs. In adjusted models, NB, measured at regular follow-up intervals, was not an independent prognostic factor for major bleeding or SSE beyond common risk scores. Patients did not report lower anticoagulation satisfaction after experiencing NB during follow-up. Our findings suggest that nuisance bleeding is not associated with increased risk for major bleeding among patients prescribed guidelinerecommended OAC treatment. However, clinicians should remain vigilant in reevaluating and controlling modifiable major bleeding risk factors in patients who experience NB.
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